Icosavax stocks are performing well amidst the Seattle-based companies new public offering. On its first day as a publicly traded company, Icosavax shares skyrocketed by 200%, ending the day at 35 dollars a share.
Other Washington state biotech companies testing the public market for the first time this year include Sana Biotechnology, Impel NeuroPharma, Nautilus Biotechnology and Absci.
“The amount of investment that is pouring into biotechnology and the life sciences is incredible,” said Dr. Leslie Alexandre, CEO of Life Sciences Washington. “The belief in the power of these technologies to prevent as well as treat some of the most serious conditions on the planet, it’s like people have woken up to that, and investors have really woken up and seen the opportunity.”